The promise of mRNA vaccines: a biotech and industrial perspective
| Autor: | Nicholas A. C. Jackson, Frank Derosa, Sanjay Gurunathan, Danilo Casimiro, Kent E. Kester |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
lcsh:Immunologic diseases. Allergy
0301 basic medicine Pharmacology 2019-20 coronavirus outbreak Vaccines Coronavirus disease 2019 (COVID-19) business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology Disease Review Article lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens lcsh:RC254-282 Biotechnology 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Infectious diseases Pharmacology (medical) Translational science lcsh:RC581-607 business 030217 neurology & neurosurgery Rapid response |
| Zdroj: | NPJ Vaccines npj Vaccines, Vol 5, Iss 1, Pp 1-6 (2020) |
| ISSN: | 2059-0105 |
| Popis: | mRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration of immunogen discovery to rapid response and multiple disease target manufacturing. A greater understanding of quality attributes that dictate translation efficiency, as well as a comprehensive appreciation of the importance of mRNA delivery, are influencing a new era of investment in development activities. The application of translational sciences and growing early-phase clinical experience continue to inform candidate vaccine selection. Here we review the state of the art for the prevention of infectious diseases by using mRNA and pertinent topics to the biotechnology and pharmaceutical industries. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|